Eli Lilly launches LillyDirect dispensing service in UK
Eli Lilly has brought its direct dispensing and delivery service, LillyDirect, to the UK. The service currently covers private prescriptions for Mounjaro, the company's tirzepatide weight loss injection, with Pharmacy2U and Onescript acting as dispensing partners.
What happened
LillyDirect is a manufacturer-run dispensing model that Eli Lilly operates in the US. The UK launch marks its first expansion into the British market. Patients with a valid private prescription for Mounjaro can use the service to have their medication dispensed and delivered directly to them through either Pharmacy2U or Onescript, both of which are registered online pharmacy providers.
The service is private prescription only at this stage — it does not cover NHS prescriptions.
Why it matters
This is unusual. Pharmaceutical manufacturers don't typically run their own dispensing infrastructure. The supply chain for medicines in the UK generally runs from manufacturer to wholesaler to pharmacy to patient. LillyDirect shortens that chain significantly, with the manufacturer sitting at the top of a vertically integrated service.
For the broader pharmacy sector, this raises real questions. If a manufacturer can funnel patients directly to two preferred dispensing partners, what does that mean for independent pharmacies or other online providers who stock the same medicine? Mounjaro demand in the UK is high, and the private market for it is competitive. Directing patients through a manufacturer-controlled gateway could shift dispensing volume away from pharmacies that have no relationship with Lilly.
Pharmacy2U is the UK's largest online pharmacy, so its inclusion here isn't surprising. Onescript is a smaller provider, but its selection alongside a major player suggests Lilly has built a two-partner model rather than granting exclusivity to one.
There's also a regulatory angle worth watching. The GPhC regulates online pharmacies, and both Pharmacy2U and Onescript must meet the same standards as any registered pharmacy. The existence of a manufacturer referral layer sitting above the dispensing process doesn't change those obligations — but it does create a new kind of commercial relationship between a medicine's maker and the people dispensing it. That's the kind of arrangement that regulators and professional bodies tend to watch closely.
GPhC exam relevance
The supply chain for medicines, roles within it, and the legal frameworks governing who can dispense what are all areas that appear in the Common Registration Assessment. Understanding that manufacturers, wholesalers, and pharmacies operate in distinct but connected roles — and that registered pharmacies remain accountable to GPhC standards regardless of referral source — is the kind of systems-level thinking the exam tests.
Mounjaro (tirzepatide) itself is worth knowing. It's a GIP and GLP-1 receptor agonist, licensed in the UK for weight management in adults with obesity or overweight alongside at least one weight-related comorbidity. The private prescription market for it has grown sharply since its launch, partly because NHS access remains restricted to specific clinical pathways.
The distinction between private and NHS prescriptions also matters for the assessment. Private prescriptions carry different legal requirements from FP10s — including the need for the prescriber's name, address, and an appropriate signature — and the supply route through a service like LillyDirect doesn't waive any of those requirements.
What's next
Watch whether LillyDirect expands to NHS prescriptions if Mounjaro secures broader NHS formulary inclusion. The NHS has been working through its approach to GLP-1 and dual agonist medicines for weight management, and any shift in access criteria could change the commercial picture entirely.
The GPhC and MHRA are likely to monitor how manufacturer-led dispensing services operate in practice, particularly around patient safety, consent, and clinical governance. Neither body has commented publicly on LillyDirect's UK arrival yet.
For pharmacy professionals, the practical question is simpler: patients may start asking whether they should use LillyDirect or their regular pharmacy. The answer involves understanding what the service does, what it doesn't cover, and whether a patient's prescription meets the eligibility criteria.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/news/business/eli-lillys-dispensing-and-delivery-service-lillydirect-comes-to-uk-BT443QVESZEUPNS6FMZT5XZERA/